Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma.
Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma.
复制标题
DOI：
10.1186/1746-1596-2-41
复制
发表时间：
2007-10-27
影响因子：
2.6
通讯作者：
中科院分区：
文献类型：
--
作者：
前列腺特异性抗原（PSA）的免疫组化检测被广泛应用于转移性前列腺腺癌的鉴别。然而，PSA在一些低分化前列腺癌中可能不表达，在一些非前列腺组织中也发现了其免疫反应性。P501s （prostein）是前列腺特异性标志物，表达于良性和恶性前列腺细胞的细胞质中。在其他正常或恶性组织中未发现。本研究的目的是评估P501s在转移性前列腺腺癌中的表达，并将其与PSA的表达进行比较。对组织芯片（TMA）标本的5微米切片进行抗p501s抗体免疫组化染色。TMA由正常供体前列腺（NDP）、前列腺腺癌（PRCA）、恶性腺体旁非肿瘤性前列腺组织（NAT）、良性前列腺增生（BPH）、高级别前列腺瘤（PIN）、淋巴结转移性腺癌（MLN）、其他部位转移性腺癌（MC）以及良性睾丸、结肠、肾上腺和肾脏样本组成。两组转移性病灶也进行PSA抗体染色。对染色的评分强度进行综合评分（0 ~ 3分）。良性腺体（评分为1.77 ~ 2.1）和恶性腺泡（评分为1.52）均可见p501s颗粒状染色，主要分布在细胞质顶端，靠近细胞核。对照组睾丸、结肠、肾上腺和肾脏均未见染色。MLN组得分为1.0分，p501阴性的病例占10%。MC病例的得分为0.64,16.7%的病例表现为p501s表达缺失。虽然转移灶中PSA抗体的阴性表达率相似，但只有2例（3.3%）MC同时出现P501S和PSA的阴性染色。P501s是良性和恶性前列腺上皮细胞的器官特异性标志物。其特有的细胞质染色模式为转移性前列腺恶性肿瘤的检测提供了一种额外的有价值的免疫标志物，即使其表达强度降低，如PSA。P501S和PSA同时染色将大大提高检出率，并能识别绝大多数转移灶。
Immunohistochemical detection of prostate specific antigen (PSA) is widely used to identify metastatic prostatic adenocarcinoma. However, PSA may not be expressed in some poorly differentiated prostatic carcinomas and its immunoreactivity has been found in some non-prostatic tissues. P501s (prostein) is a prostate-specific marker that is expressed in the cytoplasm of benign and malignant prostatic glandular cells. It has not been detected in any other normal or malignant tissues. The purpose of this study was to evaluate the expression of P501s in metastatic prostatic adenocarcinoma and compare its expression with PSA. Immunohistochemical stains with anti-P501s antibodies were performed on 5-micron sections of tissue microarray (TMA) specimens. The TMA is constructed with normal donor prostates (NDP), prostatic adenocarcinoma (PRCA), non-neoplastic prostatic tissues adjacent to malignant glands (NAT), benign prostatic hyperplasia (BPH), high-grade prostatic neoplasia (PIN), metastatic adenocarcinoma to lymph nodes (MLN), metastatic adenocarcinoma to other sites (MC), and samples of benign testis, colon, adrenal and kidney. The two groups of metastatic lesions were also subjected to stains with antibodies to PSA. A composite score (ranging from 0 to 3) was assigned to score intensity of staining. Granular staining pattern of p501s was seen in all benign glands (score = 1.77 – 2.1) and malignant acini (score = 1.52) at the apical aspect of cytoplasm, predominantly adjacent to the nuclei. No staining was observed in controls including testis, colon, adrenal and kidney. The MLN group received a score of 1.0, with 10% of cases negative for p501s. The MC cases had a score of 0.64, with 16.7% of case showing loss of p501s expression. Although the metastatic lesions demonstrated similar rate of negative expression with PSA antibody, only 2 MC cases (3.3%) showed simultaneous negative stains for both P501S and PSA. P501s is an organ specific marker for benign and malignant prostatic epithelial cells. Its characteristic cytoplasmic stain pattern provides an additional valuable immunomarker for detection of metastatic prostatic malignancy, even though the intensity of its expression is reduced, as in the case with PSA. Simultaneous stains with P501S and PSA will greatly improve the detection rate and identify a significant majority of the metastases.